{
  "trial_id": "NCT01422408",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, menopausal status, history of breast cancer, current treatment (tamoxifen or aromatase inhibitor), duration of vaginal dryness or dyspareunia, ECOG performance status, ability to read and comprehend questionnaires, use of barrier contraceptive devices, prior use of vaginal preparations, prior use of estrogen-containing medications, prior use of systemic steroids, symptoms of vaginal infection, known vaginal pathology, intolerance to topical steroid preparations, pregnancy or lactation status, diagnoses of diabetes mellitus, adrenal insufficiency, or Cushing's syndrome, prior chemotherapeutic treatment for breast cancer.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Menopause status",
          "menopausal status"
        ],
        [
          "Current endocrine therapy",
          "current treatment (tamoxifen or aromatase inhibitor)"
        ],
        [
          "Severe baseline symptoms",
          "duration of vaginal dryness or dyspareunia"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ],
        [
          "Prior cytotoxic chemotherapy received",
          "prior chemotherapeutic treatment for breast cancer"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Male",
        "Indications for endocrine therapy",
        "Dryness",
        "Dyspareunia",
        "Itching"
      ],
      "remaining_candidate_features": [
        "history of breast cancer",
        "ability to read and comprehend questionnaires",
        "use of barrier contraceptive devices",
        "prior use of vaginal preparations",
        "prior use of estrogen-containing medications",
        "prior use of systemic steroids",
        "symptoms of vaginal infection",
        "known vaginal pathology",
        "intolerance to topical steroid preparations",
        "pregnancy or lactation status",
        "diagnoses of diabetes mellitus",
        "adrenal insufficiency",
        "or Cushing's syndrome"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Menopausal Status, Race/Ethnicity, Customized, Region of Enrollment, Duration of Hormone Therapy, Baseline Vaginal Dryness Score, Baseline Dyspareunia Score, ECOG Performance Status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Menopause status",
          "Menopausal Status"
        ],
        [
          "Current endocrine therapy",
          "Duration of Hormone Therapy"
        ],
        [
          "Severe baseline symptoms",
          "Baseline Vaginal Dryness Score"
        ],
        [
          "Dryness",
          "Baseline Vaginal Dryness Score"
        ],
        [
          "Dyspareunia",
          "Baseline Dyspareunia Score"
        ],
        [
          "ECOG performance status",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Male",
        "Prior cytotoxic chemotherapy received",
        "Indications for endocrine therapy",
        "Itching"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Menopausal Status, Breast Cancer Stage, Hormone Therapy Type, Duration of Hormone Therapy, Vaginal Dryness Score, Dyspareunia Score, ECOG Performance Status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Menopause status",
          "Menopausal Status"
        ],
        [
          "Current endocrine therapy",
          "Hormone Therapy Type"
        ],
        [
          "Severe baseline symptoms",
          "ECOG Performance Status"
        ],
        [
          "Dryness",
          "Vaginal Dryness Score"
        ],
        [
          "Dyspareunia",
          "Dyspareunia Score"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Prior cytotoxic chemotherapy received",
        "Indications for endocrine therapy",
        "Itching"
      ],
      "remaining_candidate_features": [
        "Breast Cancer Stage",
        "Duration of Hormone Therapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, race, ethnicity, menopausal status, breast cancer stage, hormone therapy type, duration of hormone therapy, ECOG performance status, history of vaginal infection, vaginal pathology, diabetes mellitus, adrenal insufficiency, Cushing's syndrome, prior chemotherapy treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Menopause status",
          "menopausal status"
        ],
        [
          "Current endocrine therapy",
          "hormone therapy type"
        ],
        [
          "Prior cytotoxic chemotherapy received",
          "prior chemotherapy treatment"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Male",
        "Indications for endocrine therapy",
        "Severe baseline symptoms",
        "Dryness",
        "Dyspareunia",
        "Itching"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "breast cancer stage",
        "duration of hormone therapy",
        "history of vaginal infection",
        "vaginal pathology",
        "diabetes mellitus",
        "adrenal insufficiency",
        "Cushing's syndrome"
      ]
    }
  }
}